2017 ABSTRACTS


1- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease - Stuart Connolly

2- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - Stuart Connolly

3- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial - Stuart Connolly

4 - Contemporary incidence of mural thrombus following acute anterior STEMI complicated by new antero/apical wall motion abnormalities : insights from the multicenter MAGIC retrospective registry - Simon-Pierre Demers

5 -  Predictors of LDL-Cholesterol and Systolic Blood Pressure (SBP) Goal Attainment at One Year: Interim Data from the ISCHEMIA Trial - Jonathan Newman

6 - BNP, PIIINP, and Galectin-3 Predict Echocardiographic Diastolic Function Evolution in Patients with an Anterior Q-wave Myocardial Infarction: Insights from the REVE-2 Study - João Pedro Ferreira

7 - Combined use of Lung Ultrasound, B-type Natriuretic Peptide and Echo for Outcome Prediction in Patients with Acute HFrEF and HFpEF - Gaetano Ruocco

8 - Clinical correlates and prognostic value of bio-ADM in acute heart failure - Jozine Ter Maaten

9 - Biomarkers of reduced kidney function in patients with ST segment elevation myocardial infarction EF and HFpEF - Iryna Vyshnevska 

10 - Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide vs. furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial) - Tobias Daniel Trippel

11 -  Iron deficiency biomarkers in chronic heart failure with reduced ejection fraction: relations to clinical variables pEF - Vera Gorbachova

12 - Syncopes in Heart Failure: Mortality increases - but not in all - Djawid Hashemi (did not authorize publication)

13 - Visceral Adipose Tissue and Exercise Capacity in Heart Failure with preserved Ejection Fraction - Katlyn Koepp

14 - Dilutional versus depletional hyponatremia in acute heart failure in relation to hematocrit levels: clinical relevance and prognostic implication - Gaetano Ruocco

15 - Coronary Micro- and Macrovascular Dysfunction and Prognosis: Results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) Study -  Ahmed Albadri

16 - Comparison of Outcome of Hospitalization in Heart Failure Patients with and without History of Heart Transplantation - Sijan Basnet

17 - Weight loss after laparoscopic adjustable gastric banding surgery do not prevent the Arterial Stiffening and improvement in the Endothelial Function: A 4-Year Clinical Study - Aiste Galkine

18 - Contemporary Sex-Based Differences by Age in Presenting Characteristics, Use of an Early Invasive Strategy, and In-hospital Mortality in Patients with Non-ST-elevation Myocardial Infarction in the United States - Tanush Gupta

19 - Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Prior Coronary Artery Bypass Grafting: Trends in Utilization and a Propensity-Score Matched Analysis of In-hospital Outcomes - Tanush Gupta

20 - CYP2C19*2 and PON1 R192 polymorphisms are associated with platelet reactivity to clopidogrel in Puerto Rican Hispanics with cardiovascular disease - Dagmar Hernandez-Suarez

21 - The Effect Of Therapeutic Hypothermia On QT And Corrected QT Intervals In Patients With Cardiac Arrest And Their Association With Malignant Arrhythmias - David F. Miranda (did not authorize publication)

22 - A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): Study Design - Rajiv Agarwal

23 - Treatment with Patiromer Decreases Aldosterone in Patients with Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors - Bertram Pitt

24 - L-arginine aspartate in endothelial function, insulin resistance, adiponectin level correction in hypertensive females with rheumatoid arthritis - Oksana Sirenko

25 - High-Intensity Interval Training In Patients With Left Ventricular Assist Device - Miguel Alvarez Villela

26 - Cardioskin: A 12-lead ECG Wearable To Improve Clinical Trial Data Collection and Validate Novel Patient Pathway - Mael Mertad

27 - A novel, community-based recruitment method for a pragmatic cardiovascular clinical trial - Faraz Wilkinson

28 - Pilot Study of the Impact of Time Restricted Feeding (TRF) in Patients with Metabolic Syndrome: Study Design and Baseline Patient Characteristics - Michael Wilkinson

29 - Intra-coronary Adenosine Versus Intravenous Adenosine for Assessment of Coronary Flow Reserve in Subjects with Signs and Symptoms of Ischemia and No Obstructive Coronary Artery Disease - Ahmed Albadri

30 - Temporal Trends and Clinical Consequences of Wait-Times for Trans-Catheter Aortic Valve Replacement (TAVR): a population based study - Gabby Elbaz Greener

31 - Role of Coronary Angiography with Successful Percutaneous Coronary Intervention in Patients with Out-of-Hospital Cardiac Arrest without ST-Segment Elevation Myocardial Infarction - David F. Miranda (did not authorize publication)

32 - TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold implantation for recovery of vascular function after successful Chronic Total Occlusion recanalization: TIGER-BVS trialCardiovascular Institute, Hospital Clinic, IDIBAPS, Barcelona, Spain - Luis Ortega-Paz

33 - Undetermined Cause of Death: A pooled analysis of 9273 deaths across 9 Cardiovascular Trials - Alexander Fanaroff

34 - Availability and Use of Shared Data From Cardiometabolic Clinical Trials - Muthiah Vaduganathan

35 - Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes and established CV disease: survival estimates from EMPA-REG OUTCOME - Jyothis George

36 - Long-term Effects of Intensive vs. Standard Blood Pressure Control in "SPRINT-eligible" ACCORD BP Participants - Leo Buckley

37 - Effects of empagliflozin on cardiovascular outcomes across KDIGO risk categories: results from the EMPA-REG OUTCOME® trial - Vlado Perkovic

38 - Effects of empagliflozin on renal outcomes across KDIGO risk categories: results from the EMPA-REG OUTCOME® trial - Christoph Wanner

39 - Incidence of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction: an analysis of 6,401 patients from the Swedish Heart Failure Registry - Gianluigi Savarese

40 - Patterns and Prognostic Role of N-terminal pro-B-type Natriuretic Peptide in Heart Failure with Mid-Range vs. Preserved vs. Reduced Ejection Fraction - Gianluigi Savarese

41 - Neonatal screening of life-threatening conditions - Evgeniia Slastnikova 

42 - Atrial fibrillation in relationship to plasma biomarkers. AFISBIO - study design and rationale - Allan Böhm